Summary:
We performed a randomized study to compare ‘G-CSF alone’ (administered at dose of 10 mcg/kg/day) and ‘cyclophosphamide plus G-CSF’ (cyclophosphamide at dose of 4 g/m2 and G-CSF at dose of 10 μg/kg/day), as PBPC mobilization schedules in 52 patients with NHL or HD. Randomization was stratified according to the amount of previous chemotherapy (⩽2 and >2 lines of previous chemotherapy). Mean CD34+ cell peak in P.B., mean ‘Total CD34+ cells’ harvested and percentage of patients successfully mobilized, in the group mobilized with ‘G-CSF alone’ vs the group mobilized with ‘cyclophosphamide plus G-CSF’, were: 35.3 × 106 vs 45.8 × 106/l (P=0.3), 5.4 × 106 vs 6.8 × 106/kg (P>0.9) and 50 vs 61% (P=0.4). No differences were observed in the stratum of less pretreated patients. However, in the stratum of patients who had previously received more than two lines of chemotherapy, CD34+cell peak (P=0.05) and percentage of successful mobilization (P=0.01) were higher when ‘cyclophosphamide plus G-CSF’ was used. Using logistic regression, both age and mobilization with ‘G-CSF alone’ were significantly associated with a low CD34+ cell peak in P.B. However, in the stratum of less pretreated patients, only age was significantly associated with this risk.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277–284.
Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357.
Alegre A, Tomas JF, Martinez-Chomorro C et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997; 20: 211–217.
Desikan KR, Barlogie B, Jagannath S et al. Comparable engraftment kinetics following peripheral blood stem cell infusion mobilized with granulocyte colony stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 6: 1547–1553.
Akard LP, Thompson JM, Dugan MJ et al. Matched pair analysis of hemopoietic progenitor cell mobilisation using G-CSF vs cyclophosphamyde, etoposide and G-CSF in enhanced CD34+ cell collections are not necessarily cost-effective. Biol Blood Marrow Transplant 1999; 5: 379–385.
Kroger N, Zeiter W, Hassan HT et al. Successful mobilisation of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998; 76: 257–262.
Grimaz S, Damiani D, Michieli M et al. Mobilisation of peripheral blood progenitor cells with G-CSF alone in lymphoma patients: steady state circulating progenitor cells count predicts the autograft yield. Haematologica 2000; 85: 102–103.
Feremans SW, Le Moine F, Ravolet C et al. Optimal blood stem cell mobilisation using 10 micrograms/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study. Am J Hematol 1994; 47: 135–138.
Canales MA, Fernandez-Jimenez MC, Martin A et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin disease. Haematologica 2001; 86: 4949–4958.
Meisenberg B, Brhem T, Schmekel A et al. A combination of low-dose cyclophosphamide and colony stimulating factors is more cost-effective than granulocyte-colony stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Transfusion 1998; 38: 209–215.
Bertolini F, Lanza A, Peccatori F et al. Hemopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patient receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilisation. Ann Oncol 1998; 9: 913–916.
Kroger N, Zeiler W, Fehese N et al. Mobilizing peripheral blood stem cell with high-dose G-CSF alone is effective as with dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol 1998; 102: 1101–1106.
Cesana C, Carlo-Stella C, Regazzi E et al. CD34 cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34 cells mobilized by G-CSF. Bone Marrow Transplant 1998; 21: 561–568.
Moskowitz CH, Glassman JR, Wuest D et al. Factors affecting mobilisation of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311–316.
Narayanasami U, Kanteli R, Morelli J et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064.
Meldgaard Knudsen L, Jensen L, Gaarsdal E et al. A comparative study of sequential priming and mobilisation of progenitor cells with rh-G-CSF alone and high dose cyclophosphamide plus rh-G-CSF. Bone Marrow Transplant 2000; 26: 717–722.
Fraipont V, Sautois B, Baudoux E et al. Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF. Transfusion 2000; 40: 339–347.
Weaver CH, Tauer K, Zhen B et al. Second attempts at mobilization of peripheral blood stem cell in patients with initial low CD34+ cell yields. J Hematother 1998; 7: 241–249.
Gazitt Y, Shaughnessy P, Liu Q . Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001; 10: 167–176.
Wills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory Non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588–595.
To LB, Hylock DN . A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady phase PB and bone marrow CD34+ cells. Blood 1994; 84: 2930–2939.
Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell Lymphoma. N Engl J Med 1991; 325: 1525–1535.
Bierman PJ, Sweetenauham T, Loberizza F et al. Syngenic hematopoietic stem cell transplantation for Non Hodgkin's Lymphoma (NHL): comparison with allogenic and autologous transplants suggests a role for purging. Proc Am Soc Clin Oncol 2001; 20: 1 (abstract 15).
Jaquy C, Soree A, Lambert F et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 2000; 110: 631–637.
Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin lymphomas with polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280.
Gidali J, Feher I . Lymphoma cell contamination of PBPC: a murine model. Bone Marrow Trasplant 1999; 24: 617–620.
Demirkazik A, Kessinger A, Armitage JO et al. Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation. Bone Marrow Transplant 2001; 28: 207–212.
Passos-Coelho JL, Ross AA, Kahn DJ et al. Similar breast cancer cell contamination of single-day peripheral blood progenitor cell collections obtained after priming with hemopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996; 14: 2569–2575.
Rosillo MC, Ortuno F, Moraleda JM et al. Immune recovery after autologous or rhG-CSF primed PBPC transplantation. Eur J Haematol 1996; 56: 301–307.
Porrata LF, Gertz MA, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or Non Hodgkin's lymphoma. Blood 2001; 98: 579–585.
Akard L . Optimum methods to mobilize stem cells. J Clin Oncol 2000; 18: 3063.
Acknowledgements
We are grateful to Mike Wilkinson for the English translation of the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Milone, G., Leotta, S., Indelicato, F. et al. G-CSF Alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplant 31, 747–754 (2003). https://doi.org/10.1038/sj.bmt.1703912
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703912
Keywords
This article is cited by
-
Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials
Stem Cell Research & Therapy (2022)
-
The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation
Leukemia (2011)
-
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization
Bone Marrow Transplantation (2006)
-
Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers
Bone Marrow Transplantation (2005)